A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples

Leukemia Research

Volumn 23, Issue 7, 1999, Pages 653-663

  Illmer, Thomas ^a   Schaich, Markus ^a   Oelschlägel, Uta ^a   Nowak, Ralf ^a   Renner, Ulf ^a   Ziegs, Barbara ^a   Subat, Sabine ^a   Neubauer, Andreas ^a   Ehninger, Gerhard ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

AML; CD 34; Cytogenetics; K 562; MDR1; MIMIC; Quantitative PCR

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MESSENGER RNA; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL STRAIN K 562; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; RNA ANALYSIS; TECHNIQUE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING, COMPETITIVE; CHROMOSOME BANDING; CYTARABINE; DAUNORUBICIN; DNA, COMPLEMENTARY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, MDR; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE PROBES; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0032980043     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00076-4     Document Type: Article

References (37)

1. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845.
2. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996;10:937.
3. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997;34:25.
4. Goldsmith ME, Madden MJ, Morrow CS, Cowan KH. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 1993;268:5856.
5. Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CR, Cowan KH. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 1993;268:8290.
6. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447.
7. Hait WN, Choudhury S, Srimatkandada S, Murren JR. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J Clin Invest 1993;91:2207.
8. Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT. Various methods of analysis of mdr1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 1992;84:711.
9. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995;9:799.
10. Jaffrezou JP, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995;7:517.
11. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by antioestrogens and their major metabolites. Br J Cancer 1993;67:1189.
12. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase II alpha/ beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995;89:356.
13. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR - /efflux + and MDR + / efflux-cases. Blood 1995;86:2329.
14. Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB. Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 1997;25:1227.
15. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996;65:230.
16. Beck WT, Grogan TM, Willman CL, Cordon Cardo C, Parham DM, Kuttesch JF. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010
17. Siebert PD, Larrick JW. PCR MIMICs: competitive DNA fragments for use as internal standards in quantitative PCR. Biotechniques 1993;14:244.
18. Schaich M, Neu S, Beck J, Gekeler V, Schuler U, Ehninger G. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells. Leukemia Res 1998;21:933.
19. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V. Expression of PKC-isozyme and MDR associated genes in primary and relapsed state. Leukemia 1996;10:426.
20. Katz ED. Quantification and purification of polymerase chain reaction products by high-performance liquid chromatography. Mol Biotechnol 1996;6:79.
21. Filipits M, Suchomel RW, Lechner K, Pirker R. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Leukemia 1997;11:1073.
22. Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia (1997)11; 1086
23. Young TT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histogramms from flow systems and other sources. J Histochem Cytochem 1977;25:935.
24. Rooney DE, Czepulkowski BH. Human Cytogenetics. A Practical Approach. Oxford: Oxford University Press, 1992.
25. Gekeler V, Weger S, Probst H. mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem Biophys Res Comm 1998;169:796.
26. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996;15:2417.
27. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997;15:1796.
28. Chevillard S, Vielh P, Validire P, Marie JP, Faussat AM, Barbu V. French multicentric evaluation of mdrl gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia 1997;11:1095.
29. Lohri A, van-Hille B, Reuter J, Tichelli A, Herrmann R. mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukaemic peripheral blood and bone marrow. Acta Haematol 1997;98:1.
30. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr1 gene expression. Biochemistry 1990;29.
31. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD. Quantitative analysis of MDR1(multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proceed Nat Acad Sci USA 1990;87:7160.
32. Mrozek K, Heinonen K, de-la-Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17.
33. te Boekhorst PA, de-Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P. Predominance of functional multidrug resistance (MDR1) phenotype in CD 34 + acute myeloid leukemia cells. Blood 1993;82:3157.
34. Smeets M, Raymakers R, Vierwinden G, Pennings A, van-de-Locht L, Wessels H, Boezeman J, de-Witte T. A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 1997;96:346
35. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729.
36. Klimecki WT, Taylor CW, Dalton WS. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol 1995;15:152.
37. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451.